当前位置： SCI文献检索 > CANCER CHEMOTHERAPY AND PHARMACOLOGY期刊下所有文献 > Preoperative doxorubicin plus ifosfamide in primary soft-tissue sarcomas of the extremities.

Preoperative doxorubicin plus ifosfamide in primary soft-tissue sarcomas of the extremities.

Abstract：

:A total of 51 patients with large, primary, high-grade soft-tissue sarcomas of the extremities were treated at our institute with two preoperative and three postoperative cycles of doxorubicin plus ifosfamide/mesna. Preoperative doxorubicin was given intra-arterially for lesions of the lower extremities. Of 47 evaluable patients, 22 (47%) showed clinical responses and 21 (45%), pathologic responses. Clinical and pathologic responses, however, were not necessarily coincident in the same patient. Conservative limb-sparing surgery was performed in 41 cases (87%), and in 4 cases amputation was avoided as a result of the local improvement induced by chemotherapy. Local recurrence occurred in 12 cases (25%), 3 of which required further amputation. Although the follow-up period was only 28 months, the 4-year actuarial survival was 91% and the 4-year metastasis-free value was 69%. An evident difference existed between patients who showed a documented clinical response to chemotherapy and those who did not, the 4-year metastasis-free value being 85% and 59% (P = 0.1), respectively. Adjuvant preoperative chemotherapy may allow for limb-salvage surgical procedures in selected cases.

journal_name

Cancer Chemother Pharmacol

journal_title

Cancer chemotherapy and pharmacology

authors

Azzarelli A,Quagliuolo V,Casali P,Fissi S,Montalto F,Santoro A

subject

Has Abstract

pub_date

1993-01-01 00:00:00

pages

S210-2

eissn

0344-5704

issn

1432-0843

journal_volume

31 Suppl 2

pub_type

临床试验,杂志文章,多中心研究

相关文献

CANCER CHEMOTHERAPY AND PHARMACOLOGY文献大全
  • Hydroxyurea and hydroxamic acid derivatives as antitumor drugs.

    abstract：:Hydroxyurea has been used for decades and it is still valuable for the treatment of some types of cancer. It inhibits ribonucleotide reductase (RNR) enzyme known to be crucial in the conversion of ribonucleotides into deoxyribonucleotides. However, nowadays the main focus has shifted to structurally similar hydroxamic...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,评审

    doi：10.1007/s00280-009-0991-z

    authors： Saban N,Bujak M

    更新日期：2009-07-01 00:00:00

  • Chemomodulation of drugs involved in multidrug resistance in chronic lymphatic leukemia of the B-cell type.

    abstract：:Reduced drug accumulation may be one reason for intrinsic drug resistance in chronic lymphatic leukemia of the B-cell type (B-CLL). Immunophenotyped leukemic human B-cells from 38 cases of B-CLL were characterized for P-glycoprotein (PGP) content. In all, 30 cases of B-CLL were additionally analyzed for further parame...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00686038

    authors： Reichle A,Diddens H,Altmayr F,Rastetter J,Andreesen R

    更新日期：1994-01-01 00:00:00

  • Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study.

    abstract：PURPOSE:Fludarabine is a renally excreted agent that is an effective treatment for chronic lymphocytic leukemia (CLL), a disease predominantly of the elderly. We sought to determine whether age, renal function or pretreatment hematologic status predicted toxicity of fludarabine treatment for CLL. METHODS:We evaluated ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/s00280-002-0443-5

    authors： Martell RE,Peterson BL,Cohen HJ,Petros WP,Rai KR,Morrison VA,Elias L,Shepherd L,Hines J,Larson RA,Schiffer CA,Hurwitz HI

    更新日期：2002-07-01 00:00:00

  • Adjuvant intra-arterial 5-fluoruracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma.

    abstract：BACKGROUND:The role of adjuvant therapy in pancreatic cancer remains controversial. Gemcitabine given systemically seems to be effective; intra-arterial chemotherapy (IAC) has a deep rationale. PATIENTS AND METHODS:The goal was to evaluate the impact of postoperative IAC followed or not by systemic gemcitabine in pati...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1007/s00280-006-0200-2

    authors： Cantore M,Serio G,Pederzoli P,Mambrini A,Iacono C,Pulica C,Capelli P,Lombardi M,Torri T,Pacetti P,Pagani M,Fiorentini G

    更新日期：2006-10-01 00:00:00

  • Lack of strain-related differences in drug metabolism and efflux transporter characteristics between CD-1 and athymic nude mice.

    abstract：:CD-1 mice are commonly used in oncology metabolism and toxicity to support drug discovery and development and to examine drug metabolism and toxicity properties of new chemical entities. On the other hand, athymic nude mice are the preferred animals to investigate tumor growth inhibition. Therefore, a frequently asked...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-004-0898-7

    authors： Martignoni M,de Kanter R,Moscone A,Grossi P,Monshouwer M

    更新日期：2005-02-01 00:00:00

  • Looking for answers: the current status of neoadjuvant treatment in localized soft tissue sarcomas.

    abstract：PURPOSE:Sarcomas are a rare and heterogeneous variant of cancer. The standard of care treatment involves surgical resection with radiation in high-risk patients. Despite appropriate treatment approximately 50 % of patients will suffer and die from recurrent disease. The purpose of this article is to review the current ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,meta分析,评审

    doi：10.1007/s00280-016-3055-1

    authors： Nathenson MJ,Sausville E

    更新日期：2016-11-01 00:00:00

  • Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors.

    abstract：PURPOSE:Oral administration of 9-nitrocamptothecin (9NC), and the formation of its metabolite 9-aminocamptothecin (9AC), may be associated with high interpatient and intrapatient variability. Therefore, we evaluated the plasma pharmacokinetics and urine recovery of 9NC administered on three different schedules as part ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章

    doi：10.1007/s00280-004-0835-9

    authors： Jung LL,Ramanathan RK,Egorin MJ,Jin R,Belani CP,Potter DM,Strychor S,Trump DL,Walko C,Fakih M,Zamboni WC

    更新日期：2004-12-01 00:00:00

  • Ketotifen reverses MDR1-mediated multidrug resistance in human breast cancer cells in vitro and alleviates cardiotoxicity induced by doxorubicin in vivo.

    abstract：PURPOSE:To investigate the effect of the antihistamine ketotifen on multidrug resistance in human breast cancer cells and doxorubicin toxicity in mice. METHODS:Clonogenicity assays were used to test the effect of ketotifen on human multidrug resistant breast cancer cell lines exposed to chemotherapeutic agents. Flow c...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-003-0600-5

    authors： Zhang Y,Berger SA

    更新日期：2003-05-01 00:00:00

  • Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells.

    abstract：PURPOSE:Epigenetic agents are among the newly targeted therapeutic strategies being studied with intense interest for patients with multiple myeloma. Here, we demonstrate the antitumor activity of a phenylbutyrate-based histone deacetylase (HDAC) inhibitor, (S)-HDAC42, and identify its possible targets in myeloma cells...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-010-1501-z

    authors： Bai LY,Omar HA,Chiu CF,Chi ZP,Hu JL,Weng JR

    更新日期：2011-08-01 00:00:00

  • A new liposomal formulation of Gemcitabine is active in an orthotopic mouse model of pancreatic cancer accessible to bioluminescence imaging.

    abstract：:Despite its rapid enzymatic inactivation and therefore limited activity in vivo, Gemcitabine is the standard drug for pancreatic cancer treatment. To protect the drug, and achieve passive tumor targeting, we developed a liposomal formulation of Gemcitabine, GemLip (Ø: 36 nm: 47% entrapment). Its anti-tumoral activity ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-007-0482-z

    authors： Bornmann C,Graeser R,Esser N,Ziroli V,Jantscheff P,Keck T,Unger C,Hopt UT,Adam U,Schaechtele C,Massing U,von Dobschuetz E

    更新日期：2008-03-01 00:00:00

  • New natural products of interest under development at the National Cancer Institute.

    abstract：:Fourteen new agents of natural products origin which are under development as antitumor agents at the National Cancer Institute are discussed with reference to their sources, structures, antitumor activity, current status, and future prospects as clinically effective agents. ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00254042

    authors： Douros J,Suffness M

    更新日期：1978-01-01 00:00:00

  • Potentiation of antitumor activity of 1-phthalidyl 5-fluorouracil by acetazolamide.

    abstract：:The effect of acetazolamide (A.A.) on the antineoplastic activity of 1-phthalidyl 5-fluorouracil (PH-FU) against rat and mouse solid tumors was examined. A.A., an inhibitor of liver PH-FU hydrolase, had no antitumor activity but greatly enhanced the activity of PH-FU when coadministered. The potentiation was evaluated...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00255286

    authors： Kasai H,Tonda K,Hirata M

    更新日期：1986-01-01 00:00:00

  • Pharmacokinetic and cytotoxic studies of pegylated liposomal daunorubicin.

    abstract：:Pegylated liposomes have been studied for nearly two decades. However, fewer pharmacological studies about its application in daunorubicin (DNR) than those in doxorubicin have been reported. In order to conduct a complete pharmacokinetic study, radiolabeled DNR was encapsulated in pegylated liposomes. Its in vitro dru...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-005-0076-6

    authors： Song H,Zhang J,Han Z,Zhang X,Li Z,Zhang L,Fu M,Lin C,Ma J

    更新日期：2006-05-01 00:00:00

  • Potential limitations of in vitro clonogenic drug sensitivity assays.

    abstract：:P388 murine leukemic cells lines which were resistant (P388R) or sensitive (P388S) to adriamycin (adr) were used to evaluate the potential utility of in vitro clonogenic assays for detecting and quantitating the number of adr-resistant cells present in a cell mixture. The progeny of P388S cells that had been exposed f...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00269030

    authors： Dong GW,Preisler HD,Priore R

    更新日期：1984-01-01 00:00:00

  • Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions.

    abstract：PURPOSE:Patupilone (EPO906) is a novel potent microtubule stabilizer, which has been evaluated for cancer treatment. A novel physiologically based pharmacokinetics (PBPK) model was developed based on nonclinical data to predict the disposition of patupilone in cancer patients. METHODS:After a single intravenous dose (...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-012-1863-5

    authors： Xia B,Heimbach T,Lin TH,He H,Wang Y,Tan E

    更新日期：2012-06-01 00:00:00

  • In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers.

    abstract：PURPOSE:To compare the in vitro cytotoxicity of nedaplatin, an investigational platinum analog, with that of the standard platinum agents, cisplatin and carboplatin, against fresh human, epithelial ovarian cancers. METHODS:The Hamburger-Salmon human tumor colony-forming assay (HTCA) was used to measure the chemosensit...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s002800050604

    authors： Alberts DS,Fanta PT,Running KL,Adair LP Jr,Garcia DJ,Liu-Stevens R,Salmon SE

    更新日期：1997-01-01 00:00:00

  • Carboplatin-based combination chemotherapy for advanced carcinoma of the cervix.

    abstract：:A combination of carboplatin, vincristine, methotrexate and bleomycin (COMB) was given to 29 patients with locally advanced, metastatic or recurrent cervical carcinoma. A total of 85 cycles of chemotherapy were given, with half of the patients receiving greater than 3 cycles. Both the response rate (32.1%) and the med...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00685165

    authors： Junor E,Davies J,Habeshaw T,Kaye S,Paul J,Rankin E,Reed N,Symonds RP

    更新日期：1991-01-01 00:00:00

  • Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular schwannomas of patients with neurofibromatosis type 2.

    abstract：PURPOSE:To describe the natural growth of vestibular schwannoma in patients with neurofibromatosis type 2 and to predict tumor volume evolution in patients treated with bevacizumab and everolimus. METHODS:Clinical data, including longitudinal tumor volumes in patients treated by bevacizumab (n = 13), everolimus (n = 7...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-016-3046-2

    authors： Ouerdani A,Goutagny S,Kalamarides M,Trocóniz IF,Ribba B

    更新日期：2016-06-01 00:00:00

  • Efficacy and safety of liposome-paclitaxel and carboplatin based concurrent chemoradiotherapy for locally advanced lung squamous cell carcinoma.

    abstract：OBJECTIVE:The aim of this study was to evaluate the efficacy and toxicities of liposome-paclitaxel and carboplatin concurrent with radiotherapy for locally advanced lung squamous cell carcinoma (LSCC). METHODS:The clinical data of 38 patients with locally advanced LSCC treated with liposome-paclitaxel based concurrent...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-018-3640-6

    authors： Chen G,Sheng L,Du X

    更新日期：2018-09-01 00:00:00

  • A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies.

    abstract：PURPOSE:This phase I trial evaluated the maximum tolerated dose, safety and preliminary efficacy of lapatinib, a HER1, HER2 dual kinase inhibitor plus bortezomib, a proteasome inhibitor, in adult patients with advanced malignancies. METHODS:Patients were enrolled in a standard 3 + 3 design with lapatinib (L) 750, 1000...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-019-03947-7

    authors： Lynce F,Wang H,Petricoin EF,Pohlmann PR,Smaglo B,Hwang J,He AR,Subramaniam DS,Deeken J,Marshall J,Pishvaian MJ

    更新日期：2019-11-01 00:00:00

  • Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines by amphotericin B.

    abstract：:Resistance to the clinically used platinum-based drugs cisplatin and carboplatin represents a major limitation to their clinical effectiveness. Using cisplatin-sensitive and -resistant human ovarian carcinoma cell lines previously characterized in terms of their major underlying mechanisms of resistance, we attempted ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00686636

    authors： Sharp SY,Mistry P,Valenti MR,Bryant AP,Kelland LR

    更新日期：1994-01-01 00:00:00

  • Clinical pharmacology of intracarotid etoposide.

    abstract：:Pharmacokinetics studies were performed in ten patients who received VP-16 by intracarotid infusion at 100-300 mg/m2. VP-16 was analyzed by high-pressure liquid chromatography. ESTRIP and NONLIN were used to characterize VP-16 pharmacokinetics. VP-16 disappeared biphasically, with a t1/2 beta of 6.1 +/- 1.4 h; the tot...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00293995

    authors： Savaraj N,Feun LG,Lu K,Wallace S,Fields WS,Loo TL

    更新日期：1986-01-01 00:00:00

  • Clinical and in vitro studies of the correlation between MGMT and the effect of streptozocin in pancreatic NET.

    abstract：PURPOSE:This study aimed to determine the correlation between DNA repair enzyme O6-methylguanine DNA methyltransferase (MGMT) status and the response to streptozocin in advanced well-differentiated pancreatic neuroendocrine tumors (WD panNETs). METHODS:To test the hypothesis that MGMT deficiency was required for an al...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-018-3700-y

    authors： Hijioka S,Sakuma K,Aoki M,Mizuno N,Kuwahara T,Okuno N,Hara K,Yatabe Y

    更新日期：2019-01-01 00:00:00

  • Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).

    abstract：PURPOSE:To explore the safety and tolerability of combining two epigenetic drugs: decitabine (a DNA methyltransferase inhibitor) and panobinostat (a histone deacetylase inhibitor), with chemotherapy with temozolomide (an alkylating agent). The purpose of such combination is to evaluate the use of epigenetic priming to ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-014-2501-1

    authors： Xia C,Leon-Ferre R,Laux D,Deutsch J,Smith BJ,Frees M,Milhem M

    更新日期：2014-10-01 00:00:00

  • Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors.

    abstract：PURPOSE:Afatinib is an irreversible ErbB family blocker currently under evaluation in late-stage clinical trials. This study primarily assessed the cardiac safety, pharmacokinetics and antitumor activity of afatinib in cancer patients. METHODS:In this multicenter, Phase II, open-label, single-arm trial, 60 patients wi...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s00280-013-2286-7

    authors： Molife LR,Rudman SM,Alam S,Tan DS,Kristeleit H,Middleton G,Propper D,Bent L,Stopfer P,Uttenreuther-Fischer M,Wallenstein G,de Bono J,Spicer J

    更新日期：2013-12-01 00:00:00

  • High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study.

    abstract：:A total of 23 patients were treated at five dose escalations with high-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. The maximum tolerated doses of cyclophosphamide, cisplatin, and melphalan were 5,625, 180, and 80 mg/m2, respectively. The dose-limiting toxicity was c...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00435840

    authors： Peters WP,Stuart A,Klotman M,Gilbert C,Jones RB,Shpall EJ,Gockerman J,Bast RC Jr,Moore JO

    更新日期：1989-01-01 00:00:00

  • The pharmacologic fate of the antitumor agent 2-amino-1,3,4-thiadiazole in the dog.

    abstract：:Anticipating the renewed clinical trial of the antitumor agent 2-amino-1,3,4-thiadiazole (AT, NSC-4728), we have studied the pharmacologic fate of AT-5-14C in beagle dogs. The drug was only minimally metabolized in 5 h; the radioactivities in the urine, and particularly in the plasma, resided almost entirely in unchan...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00255274

    authors： Lu K,Loo TL

    更新日期：1980-01-01 00:00:00

  • Absorption, distribution, metabolism, and excretion (ADME) of ¹⁴C-sonidegib (LDE225) in healthy volunteers.

    abstract：PURPOSE:The absorption, distribution, metabolism, and excretion of the hedgehog pathway inhibitor sonidegib (LDE225) were determined in healthy male subjects. METHODS:Six subjects received a single oral dose of 800 mg ¹⁴C-sonidegib (74 kBq, 2.0 µCi) under fasting conditions. Blood, plasma, urine, and fecal samples wer...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-014-2468-y

    authors： Zollinger M,Lozac'h F,Hurh E,Emotte C,Bauly H,Swart P

    更新日期：2014-07-01 00:00:00

  • The minimal impact of food on the pharmacokinetics of ridaforolimus.

    abstract：PURPOSE:Ridaforolimus, a potent inhibitor of the mammalian target of rapamycin (mTOR), is under development for the treatment for solid tumors. This open-label, randomized, 3-period crossover study investigated the effect of food on the pharmacokinetics of ridaforolimus 40 mg as well as safety and tolerability of the s...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s00280-012-1897-8

    authors： Stroh M,Li X,Marsilio S,Panebianco D,Johnson-Levonas A,Juan A,Orford K,Agrawal N,Trucksis M,Wagner JA,Murphy G,Iwamoto M

    更新日期：2012-07-01 00:00:00

  • Pharmacokinetics of prednisolone in children with acute lymphoblastic leukaemia.

    abstract：:The pharmacokinetics of soluble oral prednisolone were studied during induction therapy in six children with acute lymphoblastic leukaemia. There was a three- to four-fold variation in the pharmacokinetics of total and free prednisolone. For total prednisolone, the mean elimination half-life was relatively short (1.37...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00435843

    authors： Choonara I,Wheeldon J,Rayner P,Blackburn M,Lewis I

    更新日期：1989-01-01 00:00:00